Evofem Biosciences (EVFM) Stock Price, News & Analysis

Company Overview

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.0086 to $0.0098
• 50-Day Range: $0.0089 to $0.01
• 52-Week Range: $0.0061 to $0.0150
• Volume: 1.96 million shs
• Average Volume: 409,856 shs
• Market Capitalization: $1.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Evofem Biosciences Stock Analysis - MarketRank™

Evofem Biosciences scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Evofem Biosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Evofem Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Evofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evofem Biosciences has recently decreased by 99.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evofem Biosciences does not currently pay a dividend.

Dividend Growth

Evofem Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.90

Percentage of Shares Shorted

0.00% of the float of Evofem Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Evofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evofem Biosciences has recently decreased by 99.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.50

News Sentiment

Evofem Biosciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Evofem Biosciences this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Evofem Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evofem Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Evofem Biosciences is held by insiders.

Percentage Held by Institutions

Only 0.22% of the stock of Evofem Biosciences is held by institutions.

EVFM Stock Analysis - Frequently Asked Questions

How have EVFM shares performed this year?

Evofem Biosciences' stock was trading at $0.0099 at the beginning of 2025. Since then, EVFM stock has decreased by 2.0% and is now trading at $0.0097.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences, Inc. (NASDAQ:EVFM) posted its earnings results on Friday, June, 16th. The biotechnology company reported ($1.85) EPS for the quarter, topping the consensus estimate of ($15.00) by $13.15. The biotechnology company earned $5.81 million during the quarter. Evofem Biosciences had a negative trailing twelve-month return on equity of 91.97% and a negative net margin of 46.42%.

When did Evofem Biosciences' stock split?

Shares of Evofem Biosciences reverse split on Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Evofem Biosciences?

Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F).

Company Calendar

• Last Earnings: 6/16/2023
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVFM
• CIK: 1618835
• Web: www.evofem.com
• Phone: (858) 550-1900
• Fax: 844-828-2010
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $52.98 million
• Net Margins: -46.42%
• Pretax Margin: -46.42%
• Return on Equity: -91.97%
• Return on Assets: -61.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: $11.39 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.64) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 118,656,000
• Free Float: 113,118,000
• Market Cap: $1.15 million
• Optionable: Not Optionable
• Beta: -0.99